Today: 13 June 2026
Bank of America stock edges higher after Barclays target hike as earnings near
6 January 2026
1 min read

Bank of America stock edges higher after Barclays target hike as earnings near

New York, January 6, 2026, 12:44 PM ET — Regular session

  • Bank of America shares were up about 0.4% in midday trading after Barclays lifted its price target.
  • Investors are looking to Friday’s U.S. jobs report and Bank of America’s Jan. 14 results for the next catalysts.
  • Big bank peers were mixed, with Citigroup higher and Wells Fargo lower.

Bank of America Corp (BAC.N) shares edged up about 0.4% to $57.15 in midday trading on Tuesday, after Barclays raised its price target on the lender to $71 from $59 and kept an overweight rating, TheFly reported. The stock has traded between $56.73 and $57.42.

The move keeps attention on U.S. lenders as investors position for Friday’s monthly jobs report, known as nonfarm payrolls, which can shift expectations for the Federal Reserve’s interest-rate path. Rate bets matter for banks because they influence net interest income — the gap between what a bank earns on loans and pays on deposits.

Regulation is also in focus, with U.S. officials reviewing capital and stress-test rules that determine how much equity banks must hold against losses. Morgan Stanley analysts estimated potential changes could add about $1 trillion in lending capacity for U.S. banks, according to a Reuters analysis. “Well-capitalised banks are much better at taking lending decisions,” Jose Manuel Campa, outgoing chair of the European Banking Authority, said in the report. Investing.com

JPMorgan lifted its price target on Bank of America to $61 from $58 and kept an overweight rating, MT Newswires reported. Price targets are analysts’ estimates of where a stock could trade over the next 12 months, and they often move as firms update earnings assumptions and the regulatory backdrop.

Bank of America is scheduled to report fourth-quarter results on Jan. 14, with the release set for about 6:45 a.m. ET and a conference call at 8:30 a.m. ET, the company has said. Investors will listen for updates on net interest income, credit quality and any signal on trading and investment banking momentum going into 2026.

Peers were mixed on Tuesday. Citigroup was up about 0.5%, Wells Fargo slipped about 0.4%, and JPMorgan was little changed.

Outside traditional banking, big lenders are also leaning into digital assets. Morgan Stanley filed with the U.S. Securities and Exchange Commission to launch ETFs tied to bitcoin and solana, underscoring how large banks are trying to capture fees in crypto markets as rules evolve.

But the near-term path for rates remains the main swing factor. A stronger jobs report could force markets to trim rate-cut bets, while a slower turn in regulation or a surprise rise in loan losses would test the case for bank shares.

For Bank of America, the next tests are Friday’s payrolls report and its Jan. 14 earnings, when investors will focus on management’s outlook for margins, credit and capital returns.

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure
Previous Story

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom
Next Story

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Go toTop